nodes	percent_of_prediction	percent_of_DWPC	metapath
Treprostinil—CYP2C9—Bicalutamide—prostate cancer	0.103	0.294	CbGbCtD
Treprostinil—CYP2C9—Nilutamide—prostate cancer	0.103	0.294	CbGbCtD
Treprostinil—CYP2C9—Estrone—prostate cancer	0.0615	0.176	CbGbCtD
Treprostinil—CYP2C9—Capecitabine—prostate cancer	0.0466	0.134	CbGbCtD
Treprostinil—CYP2C9—Estradiol—prostate cancer	0.0353	0.101	CbGbCtD
Treprostinil—P2RY12—prostate gland—prostate cancer	0.01	0.171	CbGeAlD
Treprostinil—PPARD—prostate gland—prostate cancer	0.00835	0.142	CbGeAlD
Treprostinil—P2RY12—epithelium—prostate cancer	0.00738	0.125	CbGeAlD
Treprostinil—PTGIR—prostate gland—prostate cancer	0.00641	0.109	CbGeAlD
Treprostinil—CYP2C9—urine—prostate cancer	0.00638	0.108	CbGeAlD
Treprostinil—PTGIR—epithelium—prostate cancer	0.00471	0.08	CbGeAlD
Treprostinil—PTGIR—renal system—prostate cancer	0.00437	0.0742	CbGeAlD
Treprostinil—PPARD—testis—prostate cancer	0.00368	0.0625	CbGeAlD
Treprostinil—PTGIR—testis—prostate cancer	0.00282	0.048	CbGeAlD
Treprostinil—Latanoprost—SLC22A1—prostate cancer	0.0027	0.664	CrCbGaD
Treprostinil—PPARD—lymph node—prostate cancer	0.00267	0.0453	CbGeAlD
Treprostinil—PTGIR—lymph node—prostate cancer	0.00205	0.0348	CbGeAlD
Treprostinil—Nadolol—ADRB2—prostate cancer	0.00137	0.336	CrCbGaD
Treprostinil—Malaise—Capecitabine—prostate cancer	0.000154	0.000435	CcSEcCtD
Treprostinil—Cough—Docetaxel—prostate cancer	0.000154	0.000435	CcSEcCtD
Treprostinil—Syncope—Capecitabine—prostate cancer	0.000153	0.000433	CcSEcCtD
Treprostinil—Pneumonia—Epirubicin—prostate cancer	0.000153	0.000433	CcSEcCtD
Treprostinil—Diarrhoea—Estradiol—prostate cancer	0.000153	0.000432	CcSEcCtD
Treprostinil—Erythema—Prednisone—prostate cancer	0.000152	0.00043	CcSEcCtD
Treprostinil—Bronchitis—Doxorubicin—prostate cancer	0.000152	0.000429	CcSEcCtD
Treprostinil—Palpitations—Capecitabine—prostate cancer	0.000151	0.000426	CcSEcCtD
Treprostinil—Decreased appetite—Etoposide—prostate cancer	0.000151	0.000425	CcSEcCtD
Treprostinil—Myalgia—Docetaxel—prostate cancer	0.00015	0.000424	CcSEcCtD
Treprostinil—Arthralgia—Docetaxel—prostate cancer	0.00015	0.000424	CcSEcCtD
Treprostinil—Chest pain—Docetaxel—prostate cancer	0.00015	0.000424	CcSEcCtD
Treprostinil—Loss of consciousness—Capecitabine—prostate cancer	0.00015	0.000424	CcSEcCtD
Treprostinil—Asthenia—Mitoxantrone—prostate cancer	0.00015	0.000422	CcSEcCtD
Treprostinil—Fatigue—Etoposide—prostate cancer	0.00015	0.000422	CcSEcCtD
Treprostinil—Cough—Capecitabine—prostate cancer	0.000149	0.000421	CcSEcCtD
Treprostinil—Pain—Etoposide—prostate cancer	0.000148	0.000418	CcSEcCtD
Treprostinil—Urinary tract infection—Epirubicin—prostate cancer	0.000148	0.000418	CcSEcCtD
Treprostinil—Dizziness—Estradiol—prostate cancer	0.000148	0.000417	CcSEcCtD
Treprostinil—Arthralgia—Capecitabine—prostate cancer	0.000146	0.000411	CcSEcCtD
Treprostinil—Chest pain—Capecitabine—prostate cancer	0.000146	0.000411	CcSEcCtD
Treprostinil—Myalgia—Capecitabine—prostate cancer	0.000146	0.000411	CcSEcCtD
Treprostinil—Haematuria—Epirubicin—prostate cancer	0.000145	0.00041	CcSEcCtD
Treprostinil—Anxiety—Capecitabine—prostate cancer	0.000145	0.000409	CcSEcCtD
Treprostinil—Oedema—Docetaxel—prostate cancer	0.000144	0.000407	CcSEcCtD
Treprostinil—Discomfort—Capecitabine—prostate cancer	0.000144	0.000406	CcSEcCtD
Treprostinil—Epistaxis—Epirubicin—prostate cancer	0.000144	0.000406	CcSEcCtD
Treprostinil—Infection—Docetaxel—prostate cancer	0.000143	0.000404	CcSEcCtD
Treprostinil—Sinusitis—Epirubicin—prostate cancer	0.000143	0.000403	CcSEcCtD
Treprostinil—Feeling abnormal—Etoposide—prostate cancer	0.000143	0.000403	CcSEcCtD
Treprostinil—Diarrhoea—Mitoxantrone—prostate cancer	0.000143	0.000402	CcSEcCtD
Treprostinil—Vomiting—Estradiol—prostate cancer	0.000142	0.000401	CcSEcCtD
Treprostinil—Pneumonia—Doxorubicin—prostate cancer	0.000142	0.0004	CcSEcCtD
Treprostinil—Gastrointestinal pain—Etoposide—prostate cancer	0.000142	0.0004	CcSEcCtD
Treprostinil—Shock—Docetaxel—prostate cancer	0.000142	0.0004	CcSEcCtD
Treprostinil—Ill-defined disorder—Prednisone—prostate cancer	0.000141	0.000399	CcSEcCtD
Treprostinil—Thrombocytopenia—Docetaxel—prostate cancer	0.000141	0.000398	CcSEcCtD
Treprostinil—Rash—Estradiol—prostate cancer	0.000141	0.000398	CcSEcCtD
Treprostinil—Dermatitis—Estradiol—prostate cancer	0.000141	0.000398	CcSEcCtD
Treprostinil—Anaemia—Prednisone—prostate cancer	0.000141	0.000397	CcSEcCtD
Treprostinil—Tachycardia—Docetaxel—prostate cancer	0.000141	0.000397	CcSEcCtD
Treprostinil—Headache—Estradiol—prostate cancer	0.00014	0.000395	CcSEcCtD
Treprostinil—Oedema—Capecitabine—prostate cancer	0.00014	0.000394	CcSEcCtD
Treprostinil—Bradycardia—Epirubicin—prostate cancer	0.000139	0.000393	CcSEcCtD
Treprostinil—Angioedema—Prednisone—prostate cancer	0.000139	0.000393	CcSEcCtD
Treprostinil—Infection—Capecitabine—prostate cancer	0.000139	0.000391	CcSEcCtD
Treprostinil—Haemoglobin—Epirubicin—prostate cancer	0.000138	0.000388	CcSEcCtD
Treprostinil—Anorexia—Docetaxel—prostate cancer	0.000137	0.000388	CcSEcCtD
Treprostinil—Malaise—Prednisone—prostate cancer	0.000137	0.000387	CcSEcCtD
Treprostinil—Shock—Capecitabine—prostate cancer	0.000137	0.000387	CcSEcCtD
Treprostinil—Rhinitis—Epirubicin—prostate cancer	0.000137	0.000387	CcSEcCtD
Treprostinil—Body temperature increased—Etoposide—prostate cancer	0.000137	0.000387	CcSEcCtD
Treprostinil—Abdominal pain—Etoposide—prostate cancer	0.000137	0.000387	CcSEcCtD
Treprostinil—Urinary tract infection—Doxorubicin—prostate cancer	0.000137	0.000387	CcSEcCtD
Treprostinil—Haemorrhage—Epirubicin—prostate cancer	0.000137	0.000386	CcSEcCtD
Treprostinil—Thrombocytopenia—Capecitabine—prostate cancer	0.000137	0.000385	CcSEcCtD
Treprostinil—Syncope—Prednisone—prostate cancer	0.000137	0.000385	CcSEcCtD
Treprostinil—Tachycardia—Capecitabine—prostate cancer	0.000136	0.000384	CcSEcCtD
Treprostinil—Pharyngitis—Epirubicin—prostate cancer	0.000136	0.000383	CcSEcCtD
Treprostinil—Oedema peripheral—Epirubicin—prostate cancer	0.000135	0.00038	CcSEcCtD
Treprostinil—Hypotension—Docetaxel—prostate cancer	0.000135	0.00038	CcSEcCtD
Treprostinil—Haematuria—Doxorubicin—prostate cancer	0.000134	0.000379	CcSEcCtD
Treprostinil—Loss of consciousness—Prednisone—prostate cancer	0.000134	0.000378	CcSEcCtD
Treprostinil—Epistaxis—Doxorubicin—prostate cancer	0.000133	0.000375	CcSEcCtD
Treprostinil—Anorexia—Capecitabine—prostate cancer	0.000133	0.000375	CcSEcCtD
Treprostinil—Nausea—Estradiol—prostate cancer	0.000133	0.000375	CcSEcCtD
Treprostinil—Vomiting—Mitoxantrone—prostate cancer	0.000133	0.000374	CcSEcCtD
Treprostinil—Sinusitis—Doxorubicin—prostate cancer	0.000132	0.000373	CcSEcCtD
Treprostinil—Rash—Mitoxantrone—prostate cancer	0.000131	0.000371	CcSEcCtD
Treprostinil—Dermatitis—Mitoxantrone—prostate cancer	0.000131	0.000371	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000131	0.00037	CcSEcCtD
Treprostinil—Headache—Mitoxantrone—prostate cancer	0.000131	0.000369	CcSEcCtD
Treprostinil—Hypotension—Capecitabine—prostate cancer	0.00013	0.000368	CcSEcCtD
Treprostinil—Insomnia—Docetaxel—prostate cancer	0.00013	0.000368	CcSEcCtD
Treprostinil—Arthralgia—Prednisone—prostate cancer	0.00013	0.000366	CcSEcCtD
Treprostinil—Myalgia—Prednisone—prostate cancer	0.00013	0.000366	CcSEcCtD
Treprostinil—Paraesthesia—Docetaxel—prostate cancer	0.000129	0.000365	CcSEcCtD
Treprostinil—Anxiety—Prednisone—prostate cancer	0.000129	0.000365	CcSEcCtD
Treprostinil—Bradycardia—Doxorubicin—prostate cancer	0.000129	0.000364	CcSEcCtD
Treprostinil—Dyspnoea—Docetaxel—prostate cancer	0.000128	0.000363	CcSEcCtD
Treprostinil—Discomfort—Prednisone—prostate cancer	0.000128	0.000361	CcSEcCtD
Treprostinil—Haemoglobin—Doxorubicin—prostate cancer	0.000127	0.000359	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000127	0.000359	CcSEcCtD
Treprostinil—Flushing—Epirubicin—prostate cancer	0.000127	0.000358	CcSEcCtD
Treprostinil—Rhinitis—Doxorubicin—prostate cancer	0.000127	0.000358	CcSEcCtD
Treprostinil—Dyspepsia—Docetaxel—prostate cancer	0.000127	0.000358	CcSEcCtD
Treprostinil—Haemorrhage—Doxorubicin—prostate cancer	0.000127	0.000357	CcSEcCtD
Treprostinil—Insomnia—Capecitabine—prostate cancer	0.000126	0.000356	CcSEcCtD
Treprostinil—Pharyngitis—Doxorubicin—prostate cancer	0.000126	0.000355	CcSEcCtD
Treprostinil—Paraesthesia—Capecitabine—prostate cancer	0.000125	0.000354	CcSEcCtD
Treprostinil—Decreased appetite—Docetaxel—prostate cancer	0.000125	0.000353	CcSEcCtD
Treprostinil—Oedema peripheral—Doxorubicin—prostate cancer	0.000125	0.000352	CcSEcCtD
Treprostinil—Asthenia—Etoposide—prostate cancer	0.000124	0.000351	CcSEcCtD
Treprostinil—Dyspnoea—Capecitabine—prostate cancer	0.000124	0.000351	CcSEcCtD
Treprostinil—Oedema—Prednisone—prostate cancer	0.000124	0.000351	CcSEcCtD
Treprostinil—Fatigue—Docetaxel—prostate cancer	0.000124	0.000351	CcSEcCtD
Treprostinil—Nausea—Mitoxantrone—prostate cancer	0.000124	0.000349	CcSEcCtD
Treprostinil—Infection—Prednisone—prostate cancer	0.000123	0.000348	CcSEcCtD
Treprostinil—Pain—Docetaxel—prostate cancer	0.000123	0.000348	CcSEcCtD
Treprostinil—Dyspepsia—Capecitabine—prostate cancer	0.000123	0.000347	CcSEcCtD
Treprostinil—Pruritus—Etoposide—prostate cancer	0.000123	0.000346	CcSEcCtD
Treprostinil—Shock—Prednisone—prostate cancer	0.000122	0.000345	CcSEcCtD
Treprostinil—Tachycardia—Prednisone—prostate cancer	0.000121	0.000342	CcSEcCtD
Treprostinil—Decreased appetite—Capecitabine—prostate cancer	0.000121	0.000342	CcSEcCtD
Treprostinil—Fatigue—Capecitabine—prostate cancer	0.00012	0.000339	CcSEcCtD
Treprostinil—Pain—Capecitabine—prostate cancer	0.000119	0.000337	CcSEcCtD
Treprostinil—Erythema—Epirubicin—prostate cancer	0.000119	0.000336	CcSEcCtD
Treprostinil—Feeling abnormal—Docetaxel—prostate cancer	0.000119	0.000335	CcSEcCtD
Treprostinil—Diarrhoea—Etoposide—prostate cancer	0.000119	0.000335	CcSEcCtD
Treprostinil—Anorexia—Prednisone—prostate cancer	0.000118	0.000334	CcSEcCtD
Treprostinil—Gastrointestinal pain—Docetaxel—prostate cancer	0.000118	0.000333	CcSEcCtD
Treprostinil—Flushing—Doxorubicin—prostate cancer	0.000118	0.000332	CcSEcCtD
Treprostinil—Tension—Epirubicin—prostate cancer	0.000117	0.00033	CcSEcCtD
Treprostinil—Nervousness—Epirubicin—prostate cancer	0.000116	0.000326	CcSEcCtD
Treprostinil—Back pain—Epirubicin—prostate cancer	0.000115	0.000325	CcSEcCtD
Treprostinil—Feeling abnormal—Capecitabine—prostate cancer	0.000115	0.000324	CcSEcCtD
Treprostinil—Dizziness—Etoposide—prostate cancer	0.000115	0.000324	CcSEcCtD
Treprostinil—Muscle spasms—Epirubicin—prostate cancer	0.000115	0.000323	CcSEcCtD
Treprostinil—Gastrointestinal pain—Capecitabine—prostate cancer	0.000114	0.000322	CcSEcCtD
Treprostinil—Body temperature increased—Docetaxel—prostate cancer	0.000114	0.000321	CcSEcCtD
Treprostinil—Abdominal pain—Docetaxel—prostate cancer	0.000114	0.000321	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000113	0.000319	CcSEcCtD
Treprostinil—Insomnia—Prednisone—prostate cancer	0.000112	0.000317	CcSEcCtD
Treprostinil—Paraesthesia—Prednisone—prostate cancer	0.000112	0.000315	CcSEcCtD
Treprostinil—Ill-defined disorder—Epirubicin—prostate cancer	0.000111	0.000312	CcSEcCtD
Treprostinil—Body temperature increased—Capecitabine—prostate cancer	0.00011	0.000311	CcSEcCtD
Treprostinil—Abdominal pain—Capecitabine—prostate cancer	0.00011	0.000311	CcSEcCtD
Treprostinil—Vomiting—Etoposide—prostate cancer	0.00011	0.000311	CcSEcCtD
Treprostinil—Erythema—Doxorubicin—prostate cancer	0.00011	0.000311	CcSEcCtD
Treprostinil—Anaemia—Epirubicin—prostate cancer	0.00011	0.000311	CcSEcCtD
Treprostinil—Dyspepsia—Prednisone—prostate cancer	0.000109	0.000309	CcSEcCtD
Treprostinil—Rash—Etoposide—prostate cancer	0.000109	0.000309	CcSEcCtD
Treprostinil—Dermatitis—Etoposide—prostate cancer	0.000109	0.000308	CcSEcCtD
Treprostinil—Headache—Etoposide—prostate cancer	0.000109	0.000307	CcSEcCtD
Treprostinil—Tension—Doxorubicin—prostate cancer	0.000108	0.000305	CcSEcCtD
Treprostinil—Decreased appetite—Prednisone—prostate cancer	0.000108	0.000305	CcSEcCtD
Treprostinil—Malaise—Epirubicin—prostate cancer	0.000107	0.000303	CcSEcCtD
Treprostinil—Fatigue—Prednisone—prostate cancer	0.000107	0.000302	CcSEcCtD
Treprostinil—Nervousness—Doxorubicin—prostate cancer	0.000107	0.000302	CcSEcCtD
Treprostinil—Syncope—Epirubicin—prostate cancer	0.000107	0.000301	CcSEcCtD
Treprostinil—Back pain—Doxorubicin—prostate cancer	0.000107	0.000301	CcSEcCtD
Treprostinil—Muscle spasms—Doxorubicin—prostate cancer	0.000106	0.000299	CcSEcCtD
Treprostinil—Palpitations—Epirubicin—prostate cancer	0.000105	0.000297	CcSEcCtD
Treprostinil—Loss of consciousness—Epirubicin—prostate cancer	0.000105	0.000295	CcSEcCtD
Treprostinil—Cough—Epirubicin—prostate cancer	0.000104	0.000293	CcSEcCtD
Treprostinil—Asthenia—Docetaxel—prostate cancer	0.000103	0.000292	CcSEcCtD
Treprostinil—Nausea—Etoposide—prostate cancer	0.000103	0.000291	CcSEcCtD
Treprostinil—Feeling abnormal—Prednisone—prostate cancer	0.000102	0.000289	CcSEcCtD
Treprostinil—Ill-defined disorder—Doxorubicin—prostate cancer	0.000102	0.000289	CcSEcCtD
Treprostinil—Pruritus—Docetaxel—prostate cancer	0.000102	0.000288	CcSEcCtD
Treprostinil—Anaemia—Doxorubicin—prostate cancer	0.000102	0.000287	CcSEcCtD
Treprostinil—Gastrointestinal pain—Prednisone—prostate cancer	0.000102	0.000287	CcSEcCtD
Treprostinil—Chest pain—Epirubicin—prostate cancer	0.000101	0.000286	CcSEcCtD
Treprostinil—Myalgia—Epirubicin—prostate cancer	0.000101	0.000286	CcSEcCtD
Treprostinil—Arthralgia—Epirubicin—prostate cancer	0.000101	0.000286	CcSEcCtD
Treprostinil—Anxiety—Epirubicin—prostate cancer	0.000101	0.000285	CcSEcCtD
Treprostinil—Discomfort—Epirubicin—prostate cancer	0.0001	0.000283	CcSEcCtD
Treprostinil—Asthenia—Capecitabine—prostate cancer	0.0001	0.000282	CcSEcCtD
Treprostinil—Malaise—Doxorubicin—prostate cancer	9.94e-05	0.00028	CcSEcCtD
Treprostinil—Syncope—Doxorubicin—prostate cancer	9.88e-05	0.000279	CcSEcCtD
Treprostinil—Pruritus—Capecitabine—prostate cancer	9.87e-05	0.000279	CcSEcCtD
Treprostinil—Diarrhoea—Docetaxel—prostate cancer	9.86e-05	0.000278	CcSEcCtD
Treprostinil—Abdominal pain—Prednisone—prostate cancer	9.83e-05	0.000277	CcSEcCtD
Treprostinil—Body temperature increased—Prednisone—prostate cancer	9.83e-05	0.000277	CcSEcCtD
Treprostinil—Palpitations—Doxorubicin—prostate cancer	9.74e-05	0.000275	CcSEcCtD
Treprostinil—Oedema—Epirubicin—prostate cancer	9.72e-05	0.000274	CcSEcCtD
Treprostinil—Loss of consciousness—Doxorubicin—prostate cancer	9.69e-05	0.000273	CcSEcCtD
Treprostinil—Infection—Epirubicin—prostate cancer	9.66e-05	0.000272	CcSEcCtD
Treprostinil—Cough—Doxorubicin—prostate cancer	9.62e-05	0.000271	CcSEcCtD
Treprostinil—Shock—Epirubicin—prostate cancer	9.56e-05	0.00027	CcSEcCtD
Treprostinil—Diarrhoea—Capecitabine—prostate cancer	9.55e-05	0.000269	CcSEcCtD
Treprostinil—Dizziness—Docetaxel—prostate cancer	9.53e-05	0.000269	CcSEcCtD
Treprostinil—Thrombocytopenia—Epirubicin—prostate cancer	9.52e-05	0.000269	CcSEcCtD
Treprostinil—Tachycardia—Epirubicin—prostate cancer	9.49e-05	0.000268	CcSEcCtD
Treprostinil—Chest pain—Doxorubicin—prostate cancer	9.38e-05	0.000265	CcSEcCtD
Treprostinil—Arthralgia—Doxorubicin—prostate cancer	9.38e-05	0.000265	CcSEcCtD
Treprostinil—Myalgia—Doxorubicin—prostate cancer	9.38e-05	0.000265	CcSEcCtD
Treprostinil—Anxiety—Doxorubicin—prostate cancer	9.35e-05	0.000264	CcSEcCtD
Treprostinil—Discomfort—Doxorubicin—prostate cancer	9.27e-05	0.000262	CcSEcCtD
Treprostinil—Anorexia—Epirubicin—prostate cancer	9.27e-05	0.000261	CcSEcCtD
Treprostinil—Dizziness—Capecitabine—prostate cancer	9.23e-05	0.00026	CcSEcCtD
Treprostinil—Vomiting—Docetaxel—prostate cancer	9.16e-05	0.000259	CcSEcCtD
Treprostinil—Rash—Docetaxel—prostate cancer	9.09e-05	0.000256	CcSEcCtD
Treprostinil—Hypotension—Epirubicin—prostate cancer	9.08e-05	0.000256	CcSEcCtD
Treprostinil—Dermatitis—Docetaxel—prostate cancer	9.08e-05	0.000256	CcSEcCtD
Treprostinil—Headache—Docetaxel—prostate cancer	9.03e-05	0.000255	CcSEcCtD
Treprostinil—Oedema—Doxorubicin—prostate cancer	9e-05	0.000254	CcSEcCtD
Treprostinil—Infection—Doxorubicin—prostate cancer	8.94e-05	0.000252	CcSEcCtD
Treprostinil—Asthenia—Prednisone—prostate cancer	8.92e-05	0.000252	CcSEcCtD
Treprostinil—Vomiting—Capecitabine—prostate cancer	8.87e-05	0.00025	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Epirubicin—prostate cancer	8.86e-05	0.00025	CcSEcCtD
Treprostinil—Shock—Doxorubicin—prostate cancer	8.85e-05	0.00025	CcSEcCtD
Treprostinil—Thrombocytopenia—Doxorubicin—prostate cancer	8.81e-05	0.000248	CcSEcCtD
Treprostinil—Rash—Capecitabine—prostate cancer	8.8e-05	0.000248	CcSEcCtD
Treprostinil—Pruritus—Prednisone—prostate cancer	8.79e-05	0.000248	CcSEcCtD
Treprostinil—Insomnia—Epirubicin—prostate cancer	8.79e-05	0.000248	CcSEcCtD
Treprostinil—Dermatitis—Capecitabine—prostate cancer	8.79e-05	0.000248	CcSEcCtD
Treprostinil—Tachycardia—Doxorubicin—prostate cancer	8.78e-05	0.000248	CcSEcCtD
Treprostinil—Headache—Capecitabine—prostate cancer	8.74e-05	0.000247	CcSEcCtD
Treprostinil—Paraesthesia—Epirubicin—prostate cancer	8.73e-05	0.000246	CcSEcCtD
Treprostinil—Dyspnoea—Epirubicin—prostate cancer	8.67e-05	0.000245	CcSEcCtD
Treprostinil—Anorexia—Doxorubicin—prostate cancer	8.57e-05	0.000242	CcSEcCtD
Treprostinil—Nausea—Docetaxel—prostate cancer	8.56e-05	0.000242	CcSEcCtD
Treprostinil—Dyspepsia—Epirubicin—prostate cancer	8.56e-05	0.000241	CcSEcCtD
Treprostinil—Diarrhoea—Prednisone—prostate cancer	8.5e-05	0.00024	CcSEcCtD
Treprostinil—Decreased appetite—Epirubicin—prostate cancer	8.45e-05	0.000238	CcSEcCtD
Treprostinil—Hypotension—Doxorubicin—prostate cancer	8.41e-05	0.000237	CcSEcCtD
Treprostinil—Fatigue—Epirubicin—prostate cancer	8.38e-05	0.000236	CcSEcCtD
Treprostinil—Pain—Epirubicin—prostate cancer	8.31e-05	0.000235	CcSEcCtD
Treprostinil—Nausea—Capecitabine—prostate cancer	8.29e-05	0.000234	CcSEcCtD
Treprostinil—Dizziness—Prednisone—prostate cancer	8.22e-05	0.000232	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Doxorubicin—prostate cancer	8.2e-05	0.000231	CcSEcCtD
Treprostinil—Insomnia—Doxorubicin—prostate cancer	8.14e-05	0.00023	CcSEcCtD
Treprostinil—Paraesthesia—Doxorubicin—prostate cancer	8.08e-05	0.000228	CcSEcCtD
Treprostinil—Dyspnoea—Doxorubicin—prostate cancer	8.02e-05	0.000226	CcSEcCtD
Treprostinil—Feeling abnormal—Epirubicin—prostate cancer	8.01e-05	0.000226	CcSEcCtD
Treprostinil—Gastrointestinal pain—Epirubicin—prostate cancer	7.95e-05	0.000224	CcSEcCtD
Treprostinil—Dyspepsia—Doxorubicin—prostate cancer	7.92e-05	0.000223	CcSEcCtD
Treprostinil—Vomiting—Prednisone—prostate cancer	7.9e-05	0.000223	CcSEcCtD
Treprostinil—Rash—Prednisone—prostate cancer	7.84e-05	0.000221	CcSEcCtD
Treprostinil—Dermatitis—Prednisone—prostate cancer	7.83e-05	0.000221	CcSEcCtD
Treprostinil—Decreased appetite—Doxorubicin—prostate cancer	7.82e-05	0.000221	CcSEcCtD
Treprostinil—Headache—Prednisone—prostate cancer	7.79e-05	0.00022	CcSEcCtD
Treprostinil—Fatigue—Doxorubicin—prostate cancer	7.76e-05	0.000219	CcSEcCtD
Treprostinil—Pain—Doxorubicin—prostate cancer	7.69e-05	0.000217	CcSEcCtD
Treprostinil—Abdominal pain—Epirubicin—prostate cancer	7.69e-05	0.000217	CcSEcCtD
Treprostinil—Body temperature increased—Epirubicin—prostate cancer	7.69e-05	0.000217	CcSEcCtD
Treprostinil—Feeling abnormal—Doxorubicin—prostate cancer	7.41e-05	0.000209	CcSEcCtD
Treprostinil—Nausea—Prednisone—prostate cancer	7.38e-05	0.000208	CcSEcCtD
Treprostinil—Gastrointestinal pain—Doxorubicin—prostate cancer	7.36e-05	0.000208	CcSEcCtD
Treprostinil—Body temperature increased—Doxorubicin—prostate cancer	7.11e-05	0.000201	CcSEcCtD
Treprostinil—Abdominal pain—Doxorubicin—prostate cancer	7.11e-05	0.000201	CcSEcCtD
Treprostinil—Asthenia—Epirubicin—prostate cancer	6.98e-05	0.000197	CcSEcCtD
Treprostinil—Pruritus—Epirubicin—prostate cancer	6.88e-05	0.000194	CcSEcCtD
Treprostinil—Diarrhoea—Epirubicin—prostate cancer	6.65e-05	0.000188	CcSEcCtD
Treprostinil—Asthenia—Doxorubicin—prostate cancer	6.45e-05	0.000182	CcSEcCtD
Treprostinil—Dizziness—Epirubicin—prostate cancer	6.43e-05	0.000181	CcSEcCtD
Treprostinil—Pruritus—Doxorubicin—prostate cancer	6.36e-05	0.00018	CcSEcCtD
Treprostinil—Vomiting—Epirubicin—prostate cancer	6.18e-05	0.000174	CcSEcCtD
Treprostinil—Diarrhoea—Doxorubicin—prostate cancer	6.15e-05	0.000174	CcSEcCtD
Treprostinil—Rash—Epirubicin—prostate cancer	6.13e-05	0.000173	CcSEcCtD
Treprostinil—Dermatitis—Epirubicin—prostate cancer	6.12e-05	0.000173	CcSEcCtD
Treprostinil—Headache—Epirubicin—prostate cancer	6.09e-05	0.000172	CcSEcCtD
Treprostinil—Dizziness—Doxorubicin—prostate cancer	5.95e-05	0.000168	CcSEcCtD
Treprostinil—Nausea—Epirubicin—prostate cancer	5.77e-05	0.000163	CcSEcCtD
Treprostinil—Vomiting—Doxorubicin—prostate cancer	5.72e-05	0.000161	CcSEcCtD
Treprostinil—Rash—Doxorubicin—prostate cancer	5.67e-05	0.00016	CcSEcCtD
Treprostinil—Dermatitis—Doxorubicin—prostate cancer	5.67e-05	0.00016	CcSEcCtD
Treprostinil—Headache—Doxorubicin—prostate cancer	5.64e-05	0.000159	CcSEcCtD
Treprostinil—Nausea—Doxorubicin—prostate cancer	5.34e-05	0.000151	CcSEcCtD
Treprostinil—CYP2C9—Metabolism—PGAM2—prostate cancer	3.06e-05	0.000131	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SULT2B1—prostate cancer	3.06e-05	0.000131	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IGF1R—prostate cancer	3.04e-05	0.00013	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—PIK3CA—prostate cancer	3.04e-05	0.00013	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.04e-05	0.00013	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—CXCL8—prostate cancer	3.03e-05	0.000129	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—JAK2—prostate cancer	3.01e-05	0.000129	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	2.99e-05	0.000128	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—CXCL8—prostate cancer	2.99e-05	0.000128	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ERBB3—prostate cancer	2.97e-05	0.000127	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FGFR2—prostate cancer	2.96e-05	0.000127	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—TP53—prostate cancer	2.94e-05	0.000126	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—LPL—prostate cancer	2.91e-05	0.000124	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SRD5A2—prostate cancer	2.9e-05	0.000124	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—AMACR—prostate cancer	2.9e-05	0.000124	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—DEGS1—prostate cancer	2.9e-05	0.000124	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP3A43—prostate cancer	2.9e-05	0.000124	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NAT1—prostate cancer	2.9e-05	0.000124	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CG—prostate cancer	2.89e-05	0.000124	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—IL2—prostate cancer	2.89e-05	0.000124	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PDGFRB—prostate cancer	2.89e-05	0.000123	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PIK3CB—prostate cancer	2.86e-05	0.000122	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—IL2—prostate cancer	2.85e-05	0.000122	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	2.85e-05	0.000122	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TERT—prostate cancer	2.84e-05	0.000121	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	2.83e-05	0.000121	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ITGB3—prostate cancer	2.81e-05	0.00012	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HSD17B1—prostate cancer	2.76e-05	0.000118	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	2.76e-05	0.000118	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—CXCL8—prostate cancer	2.75e-05	0.000117	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—INS—prostate cancer	2.74e-05	0.000117	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ERBB3—prostate cancer	2.73e-05	0.000117	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FGFR2—prostate cancer	2.73e-05	0.000116	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—HIF1A—prostate cancer	2.72e-05	0.000116	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—AKT1—prostate cancer	2.7e-05	0.000115	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CREBBP—prostate cancer	2.68e-05	0.000115	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	2.66e-05	0.000113	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—LEP—prostate cancer	2.65e-05	0.000113	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	2.64e-05	0.000113	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CAV1—prostate cancer	2.63e-05	0.000112	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—IL2—prostate cancer	2.63e-05	0.000112	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TERT—prostate cancer	2.62e-05	0.000112	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	2.62e-05	0.000112	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KDR—prostate cancer	2.6e-05	0.000111	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CD—prostate cancer	2.54e-05	0.000109	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ESR1—prostate cancer	2.53e-05	0.000108	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HIF1A—prostate cancer	2.5e-05	0.000107	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	2.49e-05	0.000106	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—AKT1—prostate cancer	2.48e-05	0.000106	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—BAD—prostate cancer	2.47e-05	0.000106	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HPGD—prostate cancer	2.46e-05	0.000105	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—B4GALT4—prostate cancer	2.46e-05	0.000105	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—LEP—prostate cancer	2.44e-05	0.000104	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CAV1—prostate cancer	2.42e-05	0.000103	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—NOS3—prostate cancer	2.4e-05	0.000103	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CG—prostate cancer	2.4e-05	0.000102	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—APC—prostate cancer	2.4e-05	0.000102	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KDR—prostate cancer	2.39e-05	0.000102	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IRS1—prostate cancer	2.37e-05	0.000101	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EGF—prostate cancer	2.37e-05	0.000101	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ESR1—prostate cancer	2.33e-05	9.96e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TNFRSF21—prostate cancer	2.32e-05	9.89e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—GSK3B—prostate cancer	2.3e-05	9.82e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—BAD—prostate cancer	2.28e-05	9.72e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—INS—prostate cancer	2.27e-05	9.69e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP7B1—prostate cancer	2.25e-05	9.62e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—MTAP—prostate cancer	2.25e-05	9.62e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CREBBP—prostate cancer	2.22e-05	9.49e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CB—prostate cancer	2.22e-05	9.47e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CG—prostate cancer	2.2e-05	9.42e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—APC—prostate cancer	2.2e-05	9.42e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	2.2e-05	9.4e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTGS2—prostate cancer	2.2e-05	9.39e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SULT1E1—prostate cancer	2.2e-05	9.38e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SRD5A1—prostate cancer	2.2e-05	9.38e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IGF1—prostate cancer	2.19e-05	9.37e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—EGFR—prostate cancer	2.18e-05	9.32e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IRS1—prostate cancer	2.18e-05	9.31e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EGF—prostate cancer	2.18e-05	9.31e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	2.13e-05	9.11e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MAP2K1—prostate cancer	2.12e-05	9.05e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—GSK3B—prostate cancer	2.12e-05	9.04e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CD—prostate cancer	2.11e-05	8.99e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	2.1e-05	8.97e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HSD17B3—prostate cancer	2.09e-05	8.95e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ACSL4—prostate cancer	2.09e-05	8.95e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—INS—prostate cancer	2.09e-05	8.91e-05	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—PIK3CA—prostate cancer	2.09e-05	8.91e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SERPINE1—prostate cancer	2.08e-05	8.9e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	2.07e-05	8.84e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—KRAS—prostate cancer	2.06e-05	8.81e-05	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—MYC—prostate cancer	2.05e-05	8.75e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CREBBP—prostate cancer	2.04e-05	8.73e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IGF1—prostate cancer	2.02e-05	8.62e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FGF2—prostate cancer	2.02e-05	8.61e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—EGFR—prostate cancer	2.01e-05	8.58e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PHGDH—prostate cancer	2.01e-05	8.58e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ARG2—prostate cancer	2.01e-05	8.58e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—UMPS—prostate cancer	2.01e-05	8.58e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	2e-05	8.53e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NOS3—prostate cancer	1.99e-05	8.49e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—LDHB—prostate cancer	1.97e-05	8.41e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MAP2K1—prostate cancer	1.95e-05	8.33e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CD—prostate cancer	1.94e-05	8.28e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP3A5—prostate cancer	1.93e-05	8.26e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—JAK2—prostate cancer	1.93e-05	8.25e-05	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—PIK3CA—prostate cancer	1.92e-05	8.2e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SERPINE1—prostate cancer	1.92e-05	8.19e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTEN—prostate cancer	1.92e-05	8.19e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—KRAS—prostate cancer	1.9e-05	8.1e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—PIK3CA—prostate cancer	1.89e-05	8.09e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MDM2—prostate cancer	1.89e-05	8.06e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PDHA1—prostate cancer	1.87e-05	7.97e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—UCP3—prostate cancer	1.87e-05	7.97e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TCN2—prostate cancer	1.87e-05	7.97e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTA3—prostate cancer	1.87e-05	7.97e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ERBB2—prostate cancer	1.86e-05	7.94e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FGF2—prostate cancer	1.86e-05	7.93e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CB—prostate cancer	1.84e-05	7.84e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NOS3—prostate cancer	1.83e-05	7.82e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—EP300—prostate cancer	1.83e-05	7.81e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HSD3B1—prostate cancer	1.78e-05	7.61e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC22A3—prostate cancer	1.78e-05	7.61e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—JAK2—prostate cancer	1.78e-05	7.6e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CXCL8—prostate cancer	1.76e-05	7.53e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PIK3CA—prostate cancer	1.74e-05	7.45e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MDM2—prostate cancer	1.74e-05	7.42e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.73e-05	7.38e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CDKN1B—prostate cancer	1.72e-05	7.36e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ERBB2—prostate cancer	1.71e-05	7.31e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTA4—prostate cancer	1.71e-05	7.29e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TBXAS1—prostate cancer	1.71e-05	7.29e-05	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—AKT1—prostate cancer	1.7e-05	7.28e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CB—prostate cancer	1.69e-05	7.22e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CASP3—prostate cancer	1.69e-05	7.21e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IL2—prostate cancer	1.69e-05	7.2e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—IL6—prostate cancer	1.68e-05	7.16e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.67e-05	7.13e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTA2—prostate cancer	1.66e-05	7.11e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ABCG5—prostate cancer	1.64e-05	7.02e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SULT1A1—prostate cancer	1.64e-05	7.02e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CCND1—prostate cancer	1.64e-05	7.02e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CTNNB1—prostate cancer	1.63e-05	6.95e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CXCL8—prostate cancer	1.62e-05	6.93e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTA1—prostate cancer	1.61e-05	6.86e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MMP9—prostate cancer	1.6e-05	6.81e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CDKN1A—prostate cancer	1.59e-05	6.79e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NAT2—prostate cancer	1.59e-05	6.78e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HSD3B2—prostate cancer	1.59e-05	6.78e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTO1—prostate cancer	1.59e-05	6.78e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PTEN—prostate cancer	1.59e-05	6.77e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CDKN1B—prostate cancer	1.59e-05	6.77e-05	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—AKT1—prostate cancer	1.57e-05	6.7e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CASP3—prostate cancer	1.55e-05	6.64e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IL2—prostate cancer	1.55e-05	6.63e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—AKT1—prostate cancer	1.55e-05	6.61e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—IL6—prostate cancer	1.54e-05	6.59e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.53e-05	6.52e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PLCB2—prostate cancer	1.52e-05	6.5e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—LRP2—prostate cancer	1.52e-05	6.5e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP2C18—prostate cancer	1.52e-05	6.5e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EP300—prostate cancer	1.51e-05	6.46e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CCND1—prostate cancer	1.51e-05	6.46e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CTNNB1—prostate cancer	1.5e-05	6.4e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—P4HB—prostate cancer	1.49e-05	6.37e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SRC—prostate cancer	1.47e-05	6.28e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MMP9—prostate cancer	1.47e-05	6.27e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CDKN1A—prostate cancer	1.46e-05	6.25e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PTEN—prostate cancer	1.46e-05	6.23e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC22A1—prostate cancer	1.45e-05	6.2e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.43e-05	6.13e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—VEGFA—prostate cancer	1.43e-05	6.12e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—AKT1—prostate cancer	1.42e-05	6.08e-05	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—AKT1—prostate cancer	1.42e-05	6.07e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—STAT3—prostate cancer	1.42e-05	6.06e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SULT2A1—prostate cancer	1.41e-05	6.04e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EP300—prostate cancer	1.39e-05	5.95e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—MED12—prostate cancer	1.39e-05	5.94e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GNG5—prostate cancer	1.38e-05	5.9e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SRC—prostate cancer	1.35e-05	5.78e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CA—prostate cancer	1.35e-05	5.78e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NCOA3—prostate cancer	1.33e-05	5.68e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—VEGFA—prostate cancer	1.32e-05	5.63e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MYC—prostate cancer	1.32e-05	5.63e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TGFB1—prostate cancer	1.31e-05	5.62e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.31e-05	5.58e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—STAT3—prostate cancer	1.31e-05	5.58e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EGFR—prostate cancer	1.29e-05	5.51e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HPGDS—prostate cancer	1.27e-05	5.42e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP2C19—prostate cancer	1.26e-05	5.39e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTT1—prostate cancer	1.23e-05	5.26e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ACHE—prostate cancer	1.23e-05	5.26e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KRAS—prostate cancer	1.22e-05	5.2e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP2A6—prostate cancer	1.22e-05	5.2e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MYC—prostate cancer	1.21e-05	5.18e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.21e-05	5.18e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TGFB1—prostate cancer	1.21e-05	5.17e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EGFR—prostate cancer	1.19e-05	5.07e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—AKR1C3—prostate cancer	1.18e-05	5.05e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PRKACB—prostate cancer	1.18e-05	5.03e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP17A1—prostate cancer	1.16e-05	4.98e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.15e-05	4.91e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KRAS—prostate cancer	1.12e-05	4.79e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CA—prostate cancer	1.12e-05	4.78e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NCOA2—prostate cancer	1.11e-05	4.74e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—AKT1—prostate cancer	1.1e-05	4.72e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TP53—prostate cancer	1.08e-05	4.62e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC5A5—prostate cancer	1.06e-05	4.52e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP2E1—prostate cancer	1.03e-05	4.42e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CA—prostate cancer	1.03e-05	4.4e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NQO1—prostate cancer	1.02e-05	4.37e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TH—prostate cancer	1.01e-05	4.31e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1e-05	4.28e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP3A4—prostate cancer	9.97e-06	4.26e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TP53—prostate cancer	9.96e-06	4.26e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	9.92e-06	4.24e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IL6—prostate cancer	9.91e-06	4.23e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP1B1—prostate cancer	9.81e-06	4.19e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GGT1—prostate cancer	9.5e-06	4.06e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NCOA1—prostate cancer	9.35e-06	4e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP19A1—prostate cancer	9.22e-06	3.94e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—AKT1—prostate cancer	9.14e-06	3.9e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IL6—prostate cancer	9.12e-06	3.89e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—RXRA—prostate cancer	8.9e-06	3.8e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	8.65e-06	3.7e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—COMT—prostate cancer	8.57e-06	3.66e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTP1—prostate cancer	8.53e-06	3.64e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—AKT1—prostate cancer	8.41e-06	3.59e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ITPR1—prostate cancer	8.39e-06	3.59e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.25e-06	3.53e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TYMS—prostate cancer	7.93e-06	3.39e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTM1—prostate cancer	7.84e-06	3.35e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—LPL—prostate cancer	7.69e-06	3.29e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP1A1—prostate cancer	7.43e-06	3.17e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ERCC2—prostate cancer	7.37e-06	3.15e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—MTHFR—prostate cancer	6.93e-06	2.96e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PPARA—prostate cancer	6.8e-06	2.9e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CAV1—prostate cancer	6.39e-06	2.73e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.1e-06	2.61e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CG—prostate cancer	5.82e-06	2.49e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—INS—prostate cancer	5.51e-06	2.35e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CREBBP—prostate cancer	5.4e-06	2.31e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CD—prostate cancer	5.12e-06	2.19e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NOS3—prostate cancer	4.83e-06	2.06e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CB—prostate cancer	4.46e-06	1.9e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTGS2—prostate cancer	4.42e-06	1.89e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTEN—prostate cancer	3.85e-06	1.65e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—EP300—prostate cancer	3.68e-06	1.57e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CA—prostate cancer	2.72e-06	1.16e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—AKT1—prostate cancer	2.22e-06	9.49e-06	CbGpPWpGaD
